Description
Seeking people with locally advanced or metastatic platinum-resistant ovarian, endometrial, or urothelial cancer for a study of an investigational drug.
Overview
Participants in this study will have a tumor biopsy tested to assess how they might respond to the investigational drug. Depending on the results of this test participants will be assigned to either get the investigational drug alone or in combination with low dose gemcitabine. Dosing will occur in 4-week cycles with infusions on days 1 and 15.
What we're hoping for
We are studying the safety and effectiveness of an investigational drug for platinum-resistant ovarian, endometrial, or urothelial cancer. This drug has not yet been approved for use as a treatment.
Additional Information
ClinicalTrials.gov Identifier: NCT05548296